Nima Farzan - Feb 11, 2022 Form 4 Insider Report for Kinnate Biopharma Inc. (KNTE)

Role: Chief Executive Officer, Director
Signature: /s/ Mark A. Meltz, attorney in fact
Stock symbol: KNTE
Transactions as of: Feb 11, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/15/2022, 03:00 PM
Previous filing: Jun 3, 2021
Next filing: Jun 3, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNTE	Employee Stock Option (right to buy)	Award	$0	+400K		$0.00	400K	Feb 11, 2022	Common Stock	400K	$10.03	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2022 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2026, subject to the Reporting Person continuing to be a service provider through each such date.

Content

One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2022 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2026, subject to the Reporting Person continuing to be a service provider through each such date.